<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38932239</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>Jun</Month><Day>12</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Is Antiviral Treatment with Remdesivir at the Acute Phase of SARS-CoV-2 Infection Effective for Decreasing the Risk of Long-Lasting Post-COVID Symptoms?</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">947</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16060947</ELocationID><Abstract><AbstractText>The aim of this study was to investigate the effects of administrating Remdesivir at the acute COVID-19 phase on developing post-COVID symptoms in previously hospitalized COVID-19 survivors by controlling factors such as age, sex, body mass index, and vaccination status. A case-control study was performed. Hospitalized COVID-19 survivors who had received intravenous Remdesivir during the acute phase (n = 216) were matched by age, sex, body mass index, and vaccination status with survivors who did not receive antiviral treatment (n = 216). Participants were asked to self-report the presence of any post-COVID symptom (defined as a symptom that started no later than three months after infection) and whether the symptom persisted at the time of study (mean: 18.4, SD: 0.8 months). Anxiety levels (HADS-A), depressive symptoms (HADS-D), sleep quality (PSQI), and severity/disability (FIC) were also compared. The multivariate analysis revealed that administration of Remdesivir at the acute COVID-19 phase was a protective factor for long-term COVID development (OR0.401, 95%CI 0.256-0.628) and specifically for the following post-COVID symptoms: fatigue (OR0.399, 95%CI 0.270-0.590), pain (OR0.368, 95% CI 0.248-0.548), dyspnea at rest (OR0.580, 95%CI 0.361-0.933), concentration loss (OR0.368, 95%CI 0.151-0.901), memory loss (OR0.399, 95%CI 0.270-0.590), hair loss (OR0.103, 95%CI 0.052-0.207), and skin rashes (OR0.037, 95%CI 0.005-0.278). This study supports the potential protective role of intravenous administration of Remdesivir during the COVID-19 acute phase for long-lasting post-COVID symptoms in previously hospitalized COVID-19 survivors.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-de-Las-Pe&#xf1;as</LastName><ForeName>C&#xe9;sar</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-3772-9690</Identifier><AffiliationInfo><Affiliation>Department of Physical Therapy, Occupational Therapy, Physical Medicine and Rehabilitation, Universidad Rey Juan Carlos, 28922 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neuroplasticity and Pain (CNAP), Sensory-Motor Interaction (SMI), Department of Health Science and Technology, Faculty of Medicine, Aalborg University, DK 9220 Aalborg, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franco-Moreno</LastName><ForeName>Anabel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Hospital Universitario Infanta Leonor-Virgen de la Torre, 28031 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruiz-Ruig&#xf3;mez</LastName><ForeName>Mar&#xed;a</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-1538-3043</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Hospital Universitario Doce de Octubre, 28041 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arrieta-Ortubay</LastName><ForeName>Estibaliz</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Hospital Universitario Doce de Octubre, 28041 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan-Murua</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-4212-7419</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Hospital Universitario Infanta Leonor-Virgen de la Torre, 28031 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Investigaci&#xf3;n Carlos III (ISCIIII), 28220 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lumbreras-Bermejo</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Hospital Universitario Doce de Octubre, 28041 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del-Valle-Loarte</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-0748-2594</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Hospital Universitario Severo Ochoa, 28911 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pellicer-Valero</LastName><ForeName>Oscar J</ForeName><Initials>OJ</Initials><Identifier Source="ORCID">0000-0002-0104-1029</Identifier><AffiliationInfo><Affiliation>Image Processing Laboratory (IPL), Universitat de Val&#xe8;ncia, Parc Cient&#xed;fic, Paterna, 46980 Val&#xe8;ncia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giordano</LastName><ForeName>Rocco</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-1331-129X</Identifier><AffiliationInfo><Affiliation>Center for Neuroplasticity and Pain (CNAP), Sensory-Motor Interaction (SMI), Department of Health Science and Technology, Faculty of Medicine, Aalborg University, DK 9220 Aalborg, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oral and Maxillofacial Surgery, Aalborg University Hospital, DK 9100 Aalborg, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arendt-Nielsen</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Center for Neuroplasticity and Pain (CNAP), Sensory-Motor Interaction (SMI), Department of Health Science and Technology, Faculty of Medicine, Aalborg University, DK 9220 Aalborg, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gastroenterology &amp; Hepatology, Mech-Sense, Clinical Institute, Aalborg University Hospital, DK 9100 Aalborg, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Steno Diabetes Center North Denmark, Clinical Institute, Aalborg University Hospital, DK 9100 Aalborg, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;n-Garrido</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Hospital Virgen del Roc&#xed;o, 41012 Sevilla, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torres-Macho</LastName><ForeName>Juan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-8860-6837</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Hospital Universitario Infanta Leonor-Virgen de la Torre, 28031 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine, Universidad Complutense de Madrid, 28040 Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>LONG-COVID-EXP-CM</GrantID><Agency>Comunidad de Madrid</Agency><Country/></Grant><Grant><GrantID>NNF21OC0067235</GrantID><Agency>Novo Nordisk Foundation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>3QKI37EEHE</RegistryNumber><NameOfSubstance UI="C000606551">remdesivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber><NameOfSubstance UI="D000409">Alanine</NameOfSubstance></Chemical><Chemical><RegistryNumber>415SHH325A</RegistryNumber><NameOfSubstance UI="D000249">Adenosine Monophosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000409" MajorTopicYN="Y">Alanine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000249" MajorTopicYN="Y">Adenosine Monophosphate</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antiviral</Keyword><Keyword MajorTopicYN="N">long-COVID</Keyword><Keyword MajorTopicYN="N">post-COVID-19</Keyword><Keyword MajorTopicYN="N">remdesivir</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>6</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>27</Day><Hour>1</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>6</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38932239</ArticleId><ArticleId IdType="pmc">PMC11209434</ArticleId><ArticleId IdType="doi">10.3390/v16060947</ArticleId><ArticleId IdType="pii">v16060947</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Liu H., Chen J., Shao W., Yan S., Ding S. Efficacy and safety of novel oral antivirals in hospitalized COVID-19 patients: A network meta-analysis of randomized clinical trials. Clin. Epidemiol. 2023;15:1041&#x2013;1053. doi: 10.2147/CLEP.S422386.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CLEP.S422386</ArticleId><ArticleId IdType="pmc">PMC10625770</ArticleId><ArticleId IdType="pubmed">37933389</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahmah L., Abarikwu S.O., Arero A.G., Essouma M., Jibril A.T., Fal A., Flisiak R., Makuku R., Marquez L., Mohamed K., et al. Oral antiviral treatments for COVID-19: Opportunities and challenges. Pharmacol. Rep. 2022;74:1255&#x2013;1278. doi: 10.1007/s43440-022-00388-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s43440-022-00388-7</ArticleId><ArticleId IdType="pmc">PMC9309032</ArticleId><ArticleId IdType="pubmed">35871712</ArticleId></ArticleIdList></Reference><Reference><Citation>Coronavirus Disease (COVID-19) Pandemic.  [(accessed on 15 July 2023)].  Available online:  https://www.who.int/emergencies/diseases/novel-coronavirus-2019.</Citation></Reference><Reference><Citation>Zur M., Peselev T., Yanko S., Rotshild V., Matok I. Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: Systematic review and network meta-analysis. Antivir. Res. 2024;221:105768. doi: 10.1016/j.antiviral.2023.105768.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2023.105768</ArticleId><ArticleId IdType="pubmed">38056602</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh R.S.P., Toussi S.S., Hackman F., Chan P.L., Rao R., Allen R., Van Eyck L., Pawlak S., Kadar E.P., Clark F., et al. Innovative Randomized phase i study and dosing regimen selection to accelerate and inform pivotal COVID-19 trial of Nirmatrelvir. Clin. Pharmacol. Ther. 2022;112:101&#x2013;111. doi: 10.1002/cpt.2603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.2603</ArticleId><ArticleId IdType="pmc">PMC9087011</ArticleId><ArticleId IdType="pubmed">35388471</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritonavir-Boosted Nirmatrelvir (Paxlovid)  [(accessed on 1 April 2024)]; Available online:  https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/ritonavir-boosted-nirmatrelvir--paxlovid-/</Citation></Reference><Reference><Citation>Malin J.J., Su&#xe1;rez I., Priesner V., F&#xe4;tkenheuer G., Rybniker J. Remdesivir against COVID-19 and other viral diseases. Clin. Microbiol. Rev. 2021;34:e00162-20. doi: 10.1128/CMR.00162-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00162-20</ArticleId><ArticleId IdType="pmc">PMC7566896</ArticleId><ArticleId IdType="pubmed">33055231</ArticleId></ArticleIdList></Reference><Reference><Citation>Remdesivir.  [(accessed on 1 April 2024)]; Available online:  https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/remdesivir/</Citation></Reference><Reference><Citation>Zadeh F., Wilson D., Agrawal D. Long COVID: Complications, underlying mechanisms, and treatment strategies. Arch. Microbiol. Immunol. 2023;7:36&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10310313</ArticleId><ArticleId IdType="pubmed">37388279</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C. Long COVID: Current definition. Infection. 2022;50:285&#x2013;286. doi: 10.1007/s15010-021-01696-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-021-01696-5</ArticleId><ArticleId IdType="pmc">PMC8438555</ArticleId><ArticleId IdType="pubmed">34519974</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano J.B., Murthy S., Marshall J.C., Relan P., Diaz J.V., WHO Clinical Case Definition Working Group on Post-COVID-19 Condition A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect. Dis. 2022;22:e102&#x2013;e107. doi: 10.1016/S1473-3099(21)00703-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C., Haupert S.R., Zimmermann L., Shi X., Fritsche L.G., Mukherjee B. Global prevalence of post COVID-19 condition or long COVID: A meta-analysis and systematic review. J. Infect. Dis. 2022;226:1593&#x2013;1607. doi: 10.1093/infdis/jiac136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac136</ArticleId><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Q., Zheng B., Daines L., Sheikh A. Long-term sequelae of COVID-19: A systematic review and meta-analysis of one-year follow-up studies on post-COVID symptoms. Pathogens. 2022;11:269. doi: 10.3390/pathogens11020269.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens11020269</ArticleId><ArticleId IdType="pmc">PMC8875269</ArticleId><ArticleId IdType="pubmed">35215212</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C., Notarte K.I., Macasaet R., Velasco J.V., Catahay J.A., Therese Ver A., Chung W., Valera-Calero J.A., Navarro-Santana M. Persistence of post-COVID symptoms in the general population two years after SARS-CoV-2 infection: A systematic review and meta-analysis. J. Infect. 2024;88:77&#x2013;88. doi: 10.1016/j.jinf.2023.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2023.12.004</ArticleId><ArticleId IdType="pubmed">38101521</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahmati M., Udeh R., Yon D.K., Lee S.W., Dolja-Gore X., McEVoy M., Kenna T., Jacob L., L&#xf3;pez S&#xe1;nchez G.F., Koyanagi A., et al. A systematic review and meta-analysis of long-term sequelae of COVID-19 2-year after SARS-CoV-2 infection: A call to action for neurological, physical, and psychological sciences. J. Med. Virol. 2023;95:e28852. doi: 10.1002/jmv.28852.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28852</ArticleId><ArticleId IdType="pubmed">37288652</ArticleId></ArticleIdList></Reference><Reference><Citation>Seb&#x151;k S., Gyires K. Long COVID and possible preventive options. Inflammopharmacology. 2023;31:2807&#x2013;2817. doi: 10.1007/s10787-023-01204-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-023-01204-1</ArticleId><ArticleId IdType="pmc">PMC10692252</ArticleId><ArticleId IdType="pubmed">37344737</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C., Torres-Macho J., Catahay J.A., Macasaet R., Velasco J.V., Macapagal S., Caldararo M., Henry B.M., Lippi G., Franco-Moreno A., et al. Is antiviral treatment at the acute phase of COVID-19 effective for decreasing the risk of long-COVID? A systematic review. Infection. 2024;52:43&#x2013;58. doi: 10.1007/s15010-023-02154-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-023-02154-0</ArticleId><ArticleId IdType="pubmed">38113020</ArticleId></ArticleIdList></Reference><Reference><Citation>Boglione L., Meli G., Poletti F., Rostagno R., Moglia R., Cantone M., Esposito M., Scianguetta C., Domenicale B., Di Pasquale F., et al. Risk factors and incidence of long-COVID syndrome in hospitalized patients: Does remdesivir have a protective effect? QJM. 2022;114:865&#x2013;871. doi: 10.1093/qjmed/hcab297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/qjmed/hcab297</ArticleId><ArticleId IdType="pmc">PMC8690187</ArticleId><ArticleId IdType="pubmed">34850210</ArticleId></ArticleIdList></Reference><Reference><Citation>Badenes Bonet D., Caguana V&#xe9;lez O.A., Duran Jord&#xe0; X., Comas Serrano M., Posso Rivera M., Admetll&#xf3; M., Herranz Blasco A., Cuadrado Godia E., Marco Navarro E., Martin Ezquerra G., et al. Treatment of COVID-19 during the acute phase in hospitalized patients decreases post-acute sequelae of COVID-19. J. Clin. Med. 2023;12:4158. doi: 10.3390/jcm12124158.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm12124158</ArticleId><ArticleId IdType="pmc">PMC10299438</ArticleId><ArticleId IdType="pubmed">37373850</ArticleId></ArticleIdList></Reference><Reference><Citation>Nevalainen O.P.O., Horstia S., Laakkonen S., Rutanen J., Mustonen J.M.J., Kalliala I.E.J., Ansakorpi H., Kreivi H.R., Kuutti P., Paajanen J., et al. Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial. Nat. Commun. 2022;13:6152. doi: 10.1038/s41467-022-33825-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-33825-5</ArticleId><ArticleId IdType="pmc">PMC9579198</ArticleId><ArticleId IdType="pubmed">36257950</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedman E., Lj&#xf3;tsson B., Blom K., El Alaoui S., Kraepelien M., R&#xfc;ck C., Andersson G., Svanborg C., Lindefors N., Kaldo V. Telephone versus internet administration of self-report measures of social anxiety, depressive symptoms, and insomnia: Psychometric evaluation of a method to reduce the impact of missing data. J. Med. Internet Res. 2013;15:e229. doi: 10.2196/jmir.2818.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/jmir.2818</ArticleId><ArticleId IdType="pmc">PMC3806436</ArticleId><ArticleId IdType="pubmed">24140566</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann-Lingen C., Buss U., Snaith R.P. Hospital Anxiety and Depression Scale&#x2014;Deutsche Version (HADS-D) Verlag Hans Huber; Bern, Switzerland: 2011.</Citation></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C., Rodr&#xed;guez-Jim&#xe9;nez J., Palacios-Ce&#xf1;a M., de-la-Llave-Rinc&#xf3;n A.I., Fuensalida-Novo S., Florencio L.L., Ambite-Quesada S., Ortega-Santiago R., Arias-Bur&#xed;a J.L., Liew B.X.W., et al. Psychometric properties of the Hospital Anxiety and Depression Scale (HADS) in previously hospitalized COVID-19 patients. Int. J. Environ. Res. Public. Health. 2022;19:9273. doi: 10.3390/ijerph19159273.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph19159273</ArticleId><ArticleId IdType="pmc">PMC9367824</ArticleId><ArticleId IdType="pubmed">35954630</ArticleId></ArticleIdList></Reference><Reference><Citation>Olss&#xf8;n I., Mykletun A., Dahl A.A. The Hospital Anxiety and Depression Rating Scale: A cross-sectional study of psychometrics and case findings abilities in general practice. BMC Psychiatry. 2005;5:46. doi: 10.1186/1471-244X-5-46.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-244X-5-46</ArticleId><ArticleId IdType="pmc">PMC1343544</ArticleId><ArticleId IdType="pubmed">16351733</ArticleId></ArticleIdList></Reference><Reference><Citation>Buysse D.J., Reynolds C.F., Monk T.H., Berman S.R., Kupfer D.J. The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Res. 1989;28:193&#x2013;213. doi: 10.1016/0165-1781(89)90047-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0165-1781(89)90047-4</ArticleId><ArticleId IdType="pubmed">2748771</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam S.P., Tsui E., Chan K.S., Lam C.L., So H.P. The validity and reliability of the functional impairment checklist (FIC) in the evaluation of functional consequences of severe acute respiratory distress syndrome (SARS) Qual. Life Res. 2006;15:217&#x2013;231. doi: 10.1007/s11136-005-1463-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11136-005-1463-5</ArticleId><ArticleId IdType="pmc">PMC7088534</ArticleId><ArticleId IdType="pubmed">16468078</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C., Palacios-Ce&#xf1;a M., Rodr&#xed;guez-Jim&#xe9;nez J., de-la-Llave-Rinc&#xf3;n A.I., Fuensalida-Novo S., Cigar&#xe1;n-M&#xe9;ndez M., Florencio L.L., Ambite-Quesada S., Ortega-Santiago R., Pardo-Hern&#xe1;ndez A., et al. Psychometric properties of the Functional Impairment Checklist (FIC) as a disease-specific patient-reported outcome measure (PROM) in previously hospitalized COVID-19 survivors with long-COVID. Int. J. Environ. Res. Public Health. 2022;19:11460. doi: 10.3390/ijerph191811460.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph191811460</ArticleId><ArticleId IdType="pmc">PMC9517100</ArticleId><ArticleId IdType="pubmed">36141732</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes L.D., Ingram J., Sculthorpe N.F. More than 100 persistent symptoms of SARS-CoV-2 (Long COVID): A scoping review. Front. Med. 2021;8:750378. doi: 10.3389/fmed.2021.750378.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.750378</ArticleId><ArticleId IdType="pmc">PMC8591053</ArticleId><ArticleId IdType="pubmed">34790680</ArticleId></ArticleIdList></Reference><Reference><Citation>Chuang M.H., Wu J.Y., Liu T.H., Hsu W.H., Tsai Y.W., Huang P.Y., Lai C.C. Efficacy of nirmatrelvir and ritonavir for post-acute COVID-19 sequelae beyond 3 months of SARS-CoV-2 infection. J. Med. Virol. 2023;95:e28750. doi: 10.1002/jmv.28750.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28750</ArticleId><ArticleId IdType="pubmed">37185834</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., Choi T., Al-Aly Z. Association of treatment with Nirmatrelvir and the risk of post-COVID-19 condition. JAMA Intern. Med. 2023;183:554&#x2013;564. doi: 10.1001/jamainternmed.2023.0743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2023.0743</ArticleId><ArticleId IdType="pmc">PMC10037200</ArticleId><ArticleId IdType="pubmed">36951829</ArticleId></ArticleIdList></Reference><Reference><Citation>Geng L.N., Bonilla H., Hedlin H., Jacobson K.B., Tian L., Jagannathan P., Yang P.C., Subramanian A.K., Liang J.W., Shen S., et al. Nirmatrelvir-Ritonavir and symptoms in adults with post-acute sequelae of SARS-CoV-2 infection: The STOP-PASC Randomized Clinical Trial. JAMA Intern. Med. 2024:e242007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11161857</ArticleId><ArticleId IdType="pubmed">38848477</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Wei Y., Hung C.T., Lin G., Jiang X., Li C., Jia K.M., Yam C.H.K., Chow T.Y., Ho J.Y., et al. Association of nirmatrelvir-ritonavir with post-acute sequelae and mortality in patients admitted to hospital with COVID-19: A retrospective cohort study. Lancet Infect. Dis. 2024 doi: 10.1016/S1473-3099(24)00217-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(24)00217-2</ArticleId><ArticleId IdType="pubmed">38710190</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannou G.N., Berry K., Rajeevan N., Li Y., Mutalik P., Yan L., Bui D., Cunningham F., Hynes D.M., Rowneki M., et al. Effectiveness of Nirmatrelvir-Ritonavir against the development of post-COVID-19 conditions among U.S. Veterans: A Target Trial Emulation. Ann. Intern. Med. 2023;176:1486&#x2013;1497. doi: 10.7326/M23-1394.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M23-1394</ArticleId><ArticleId IdType="pmc">PMC10620954</ArticleId><ArticleId IdType="pubmed">37903369</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran V.T., Riveros C., Clepier B., Desvarieux M., Collet C., Yordanov Y., Ravaud P. Development and validation of the long COVID symptom and impact tools, a set of patient-reported instruments constructed from patients&#x2019; lived experience. Clin. Infect. Dis. 2022;74:278&#x2013;287. doi: 10.1093/cid/ciab352.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab352</ArticleId><ArticleId IdType="pmc">PMC8135558</ArticleId><ArticleId IdType="pubmed">33912905</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>